Britain and America have reached a landmark bilateral deal that will guarantee zero tariffs on UK pharmaceutical shipments being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to raise funding on pharmaceuticals through the public health system. This move secures that duties on these key goods will be held at nothing for a timeframe of the next three years.
This deal follows previous statements to significantly raise duties on branded drug products, with potential rates floated reaching one hundred percent.
"This deal between the United Kingdom bolsters the international landscape for innovative medicines and brings much-needed fairness to American-British drug exports," an announcement said.
Trade Significance
Pharmaceuticals represent one of the the United Kingdom's largest goods shipped to the US, which is easily the primary market for large companies like GSK and AstraZeneca.
Statistics indicate that in the 12 months prior to last September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This figure represented a significant portion of all goods exports in that span.
"This deal secures work, increases capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," a government official remarked.
Key UK Commitments
The deal entails several notable pledges from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the next decade.
- Rebate Cap: The sum drug companies must pay back to the NHS to stay within budget will be restricted at 15%. Last year, rebates topped 20%.
Recent Tensions
This agreement follows a long-running tension between the pharmaceutical industry and the ministers over medicine costs and regulatory access.
These tensions were exacerbated by claims that US consumers were paying several times more for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been announced toward US facilities.
A senior figure stated that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
